The newly discovered cell type (yellow) shown clustering around a prostate cancer nerve bundle.

Garvan-Institute-prostate-cancer

Scientists have identified a new cell type and discovered that many normal-looking prostate cells already harbour cancer-related changes.

Cellular ‘atlas’ of prostate cancer opens new avenues for earlier detection

Anthony-Joshua.jpg

A clinical trials network – the NSW Early Phase Clinical Trials Alliance – is allowing more cancer patients to access crucial early-stage clinical trials.

NSW network facilitating access to life-saving clinical trials

Carlson-Tsui-Garvan-Institute

Dr Carlson Tsui is leading a new research lab dedicated to the ‘stem-like’ immune cells that power long-term responses to immunotherapy.

Garvan recruits expert to boost immune defence against cancer

Clare-Puttick-News-Banner.png

Dr Clare Puttick will establish a new lab focused on understanding how lung and breast tumours evade the body’s natural defences.

Garvan welcomes computational biologist to decode cancer’s immune escape tactics

Immunoflurescence microscopy image of developing liver, gallbladder and pancreas

Liver-cancer-clinical-trial_news_Garvan-high-2.jpg

A novel liver cancer trial is currently recruiting participants, testing two drugs to prevent cancer from returning

Liver cancer clinical trial launches, targeting the environment around tumours

Marina-Pajic-Garvan-Institute

A multicentre Australian study will combine chemotherapy with drugs that weaken the barrier around pancreatic cancer.

New clinical trials to target pancreatic cancer’s protective shield

Mate-Biro-News-120126.png

Garvan researchers are developing a new approach that transforms the immune system’s natural killer cells into therapeutic delivery systems for treating hard-to-reach tumours.

Engineering immune cells to target pancreatic cancer

A breakthrough study of over 450 pancreatic cancer genomes, published today in Nature, has shown that pancreatic cancer is in fact four distinct diseases. The study was led by researchers from the Australian Pancreatic Cancer Genome Initiative, Garvan, the University of Melbourne and the University of Queensland. 

Genomics yields a new understanding of pancreatic cancer

Professor Chris Goodnow and Dr Manu Singh

Chris Goodnow and Manu Singh at the Garvan Institute

Scientists have identified mutated immune cell clones that could point to improved treatment for refractory coeliac disease.

‘Rogue’ immune cells explain why a gluten-free diet fails in some coeliac patients

Diabetic checking Blood glucose.jpg

Garvan trial finds that using a common and inexpensive drug reduces insulin needs in type 1 diabetes, opening doors for improved management of the condition

Use of common drug reduces insulin needs in type 1 diabetes

Garvan congratulates Professor Jerry Greenfield on receiving a Millennium Award from Diabetes Australia to support an innovative clinical study in type 1 diabetes.

Professor Jerry Greenfield receives prestigious award

ACRF TMA MSI Image-2.png

These insights will help design better treatments to tackle treatment resistance and metastasis 

Australian-first imaging centre to provide unprecedented detail on how cancers interact with their microenvironment

Dannel Yeo Jessica Chitty Garvan Institute.jpg

Garvan researchers have received new funding support to target biological barriers to chemotherapy and develop blood tests to predict treatment response.


Pancreatic cancer projects receive backing at Garvan

Jonathan Nguyen, Associate Professors Owen Siggs and Jodie Ingles, and PhD student Lucas Thomas from the Genomics of Rare Disease Registry

Genomics of Rare Disease Registry - Garvan Institute - low res.jpg

Garvan’s Genomics of Rare Disease Registry will broaden its reach thanks to a funding boost.

Major expansion of national rare disease registry to reach more Australian families

David Croucher - Garvan Institute

Garvan researchers have identified a drug that can overcome treatment resistance in relapsed neuroblastoma.

Potential treatment to bypass resistance in deadly childhood cancer

Garvan researchers will develop treatments to break through tumour defences and blood tests that could catch this deadly disease years earlier than current methods.

Newly funded projects to target pancreatic cancer’s protective shield and improve early detection

Findings published in the July edition of the prestigious Journal of Experimental Medicine may offer new hope to people suffering from a previously unsuspected form of lupus. The research, undertaken by Garvan's Professor Fabienne Mackay, suggests a form of the disease that does not respond to current treatments. If proven to be correct, her findings will change clinical thinking and so bring about changes in patient management and in clinical trial protocols.

Have we uncovered a new form of lupus?

Dr Andrew Nash, Lauren Adlam (Sutton) and Dr Neil Söderlund

Board-Announcement-24-Oct-Hero Banner.jpg

Garvan’s boards welcome three new appointments  

New appointments to Garvan boards bring breadth of leadership credentials

Associate Professor Jodie Ingles and Dr Laura Yeates

Australian-Hearts_news_Garvan-Institute.jpg

Garvan researchers are building a national database of inherited heart diseases to predict and prevent life-threatening complications. 

National registry offering hope for families with genetic heart conditions

Tongan_King_and_Queen_visit_Garvan_Institute

Their Majesties’ visit to the Sydney medical research institute highlights growing collaboration between Pasifika communities and genetic medicine initiatives.

Tongan King and Queen meet genomics research leaders during official visit to the Garvan Institute

GENIE-news_Garvan-Institute.jpg

Study now recruiting participants to better diagnose inborn errors of immunity 

New Garvan study aims to improve early detection of genetic immune disorders

Dr Kate Jeffrey, Ms Sue Horlin and Ms Ilana Atlas AO

Board-members-composite-Garvan.jpg

Two new Garvan board appointments enhance the Institute’s governance capabilities in both scientific innovation and organisational management.

Garvan board appointments bring scientific and strategic leadership

Hasindu_Gamaarachchi_Garvan

Dr Hasindu Gamaarachchi has been recognised for computational innovations that dramatically reduce the computing power needed for genomic analysis, democratising access to this transformative technology.

Garvan researcher wins Eureka Prize for faster genomic analysis

Ensuring-more-diversity-in-genomics-research_Garvan-Institute.jpg

New project will make genomics more representative

Ensuring more diversity in genomics research

Art_of_Discovery_at_the_Garvan_Institute

The Garvan Institute is opening its doors to the public, offering a rare opportunity to see the beauty of medical research through an exhibition of scientific imagery. 

Garvan’s Art of Discovery exhibition is welcoming visitors for National Science Week

Associate Professor Liz Caldon and Dr Sarah Alexandrou

Liz Caldon and Sarah Alexandrou from the Garvan Institute low res.jpg

A team of Garvan scientists has discovered that inactivation of a stress pathway makes ER+ breast cancer cells ignore stress signals, allowing them to evade treatment.

Researchers uncover potential mechanism driving treatment resistance in common breast cancer

The-AllClear-leadership-team.jpg

The National Breast Cancer Foundation’s landmark investment will drive research focused on stopping breast cancer recurrence.

Historic $25 million grant backs Garvan breast cancer research

230709_Jodie-Ingles_Garvan-Institute

The Elusive Hearts Study will give families with genetically unknown inherited heart conditions a second chance at diagnosis.

Boost for national cardiac genetic testing research program

christoper-goodnow_megan-barnet_Garvan-Institute.jpg

Garvan researchers have discovered new pathways that may explain differences in the way people with cancer respond to immunotherapy  

New mechanism found to supercharge the immune system against cancers

Chris Goodnow Garvan Institute

The prestigious award recognises Professor Goodnow’s innovative work on immune system breakdowns and chronic autoimmune disease.

Professor Chris Goodnow honoured with Max Cooper Prize in Immunology

Hetrogenous gene expression in a tumour

Garvan researchers have developed a new AI tool which could be integrated into cancer diagnostics to better inform treatment.

AI tool set to transform characterisation and treatment of cancers

Dr-Louise-Rabbitt_Garvan-Institute.jpg

Experienced veterinarian and facility manager Dr Louise Rabbitt will lead the crucial research facility as current head Dr Jenny Kingham announces retirement.

Dr Louise Rabbitt appointed as new head of Australian BioResources

Professor-Daniel-MacArthur_Garvan-Institute_2025.jpg

Leader of the Centre for Population Genomics internationally recognised for transformative contributions to global genomic research.

Garvan researcher receives prestigious European genomics award

Dr Rama Dhenni and Professor Tri Phan

Scientists have uncovered why vaccines can elicit a stronger immune response if they are administered in the same arm.

Left or right arm? New research reveals why vaccination site matters for immune response

Associate Professors Clare Stirzaker and David Croucher

Clare_Stirzaker_and_David_Croucher_Garvan_Institute.jpg

Cancer Council NSW grants will support innovative approaches to monitoring breast cancer recurrence and improving treatment effectiveness for high-risk neuroblastoma.

Breast cancer blood test and childhood cancer projects given the green light

Ira_Deveson_Garvan_Institute

A major new Garvan-led research project will develop advanced DNA analysis methods to provide a more detailed picture of the human genome, improving access to the benefits of genetic medicine for diverse populations.

Research to unlock life-changing benefits from advanced DNA analysis

Ira_Deveson_Garvan_Institute-2.jpg

Dr Ira Deveson will receive the Ruth Stephens Gani Medal at the 2025 Science at the Shine Dome event, in recognition of his contributions to clinical genomics and bioinformatics. 

Australian Academy of Science honours Garvan genomics researcher

Maté Biro Garvan Institute.jpg

Associate Professor Maté Biro brings specialised expertise in how immune cells interact with tumours to the Institute’s Cancer Ecosystems Program.


Garvan appoints leading expert in cancer-immune interactions

Associate Professors Owen Siggs and Jodie Ingles are leading the Genomics of Rare Disease Registry

Jodie_Ingles_and_Owen_Siggs_Garvan_Institute-2.jpg

Sydney researchers are recruiting for a study aimed at improving diagnosis, treatment and support for an estimated two million people who live with rare genetic diseases in Australia alone.

Recruiting now: study to uncover genetic cause of rare diseases

Sophie Hespe
and Associate Professor Jodie Ingles

Jodie_Sophie_Garvan-Institute.jpg

Garvan researchers update guidelines on which genes should – and which should not – be included in genetic testing for patients with hypertrophic cardiomyopathy.

Researchers refine genetic test panel for inherited cardiomyopathy

Dr-Shona-Ritchie_Garvan-Institute.jpg

Dr Shona Ritchie has received Cancer Institute NSW funding to explore how a cholesterol-regulating medication could make existing chemotherapies more effective against pancreatic cancer.

Garvan researcher to investigate cholesterol-lowering drug for pancreatic cancer treatment

221020_Katherine-Samaras_Garvan-Institute

A commonly used treatment for diabetes may hold the key to slowing cognitive decline to prevent dementia. This Phase 3 clinical trial is seeking participants.

Clinical trial will test drug treatment for prevention of dementia

Professor Paul Timpson, Dr Cecilia Chambers and Dr David Herrmann

Professor-Paul-Timpson_Dr-Cecilia-Chambers_Dr-David-Herrmann_Garvan-Institute.jpg

Scientists identify a molecule that fuels pancreatic cancer spread to the liver, opening new avenues for treatment.

A metabolism switch that could help stop the spread of pancreatic cancer

Dr Brooke Pereira with her Excellency the Honourable Ms Sam Mostyn AC at the Fulbright Gala

Brooke-Pereira-Fulbright-Gala-Garvan-Institute.jpg

Garvan’s Dr Brooke Pereira has been awarded the prestigious Fulbright Scholarship to embark on an exchange to the US, where she will investigate new therapy targets for pancreatic cancer.

Dr Brooke Pereira awarded Fulbright Scholarship

Clockwise from top left: Dr Kylie James, Dr Curtis Cai, Dr Ruebena Dawes, Dr Etienne Masle-Farquhar and Dr Drew Neavin

Kylie-James-Curtis-Cai-Ruebena-Dawes-Etienne-Masle-Farquhar-Drew-Neavin-v3.jpg

National Health and Medical Research Council backs five Garvan scientists to pursue solutions for complex diseases affecting millions of Australians.

Next wave of medical research backed by national grants

Seyhan-Yazar-Garvan-Institute

A new Garvan study will investigate how to spot multiple sclerosis before symptoms appear, to help prevent long-term nerve damage.

New research to target hidden signs of MS

Dr Alexandra Butters and Associate Professor Jodie Ingles 

jodei-and-alex-composite-v2.jpg

A case report of a misclassified cardiomyopathy gene variant highlights the need for more diversity in genomics.

Australian researchers call for greater diversity in genomics

Ankur-Sharma-Garvan-Institute

An international research project has been greenlit under the NHMRC ASPIRE program, bringing together Australian and Japanese experts to create a detailed spatial map of cancer and its immune environment.

Major Australia-Japan cancer mapping project to guide precision medicine

Cindy-Ma-Geetha-Rao-Garvan-Institute

Study of an immune messenger offers fresh hope for patients with allergies, asthma and other immune disorders.

Immune ‘mystery molecule’ points to potential targets for allergies and other immune conditions

Chris-Goodnow-Garvan-Institute

Landmark discoveries about the immune system’s protective mechanisms earn global recognition for Garvan researcher.

Professor Christopher Goodnow awarded prestigious Crafoord Prize

Professor Chris Goodnow, Dr Clara Young and Dr Dan Suan

Chris-Goodnow-Clara-Young-Dan-Suan-Garvan-Institute.jpg

Garvan researchers have uncovered how chronic hepatitis C infection leads to autoimmune disease, which opens new paths for treatments.

‘Perfect storm’ of mutations drives infection-triggered autoimmune disease

Clockwise from left: Dr Drew Neavin, Dr Brooke Pereira, Dr Andre Reis, Dr Kendelle Murphy, Dr Marcia Munoz and Professor Daniel Christ

_NHMRC-Ideas-and-Development-Grants_banner.jpg

Six research teams at Garvan have been awarded significant funding to pursue solutions across antibody therapy, inflammatory bowel disease, pancreatic cancer, bipolar disorder and genomic medicine.

Garvan research boosted by NHMRC Ideas and Development Grants

kimberley-bracelet1680x1120.png

In August, we celebrate a significant milestone with Paspaley reaching $2 million in donations in support of Garvan’s cancer research. 

Paspaley’s jewellery with purpose

antibody-illustration-Garvan-Institute

New insights into how checkpoint inhibitors affect the immune system could improve cancer treatment.

Study reveals cause of common cancer immunotherapy side effect

Brooke_Pereira_Kendelle_Murphy_Garvan_Institute

The projects are targeting the dense scarring around pancreatic tumours that hinders the success of chemotherapy.

Pancreatic cancer projects funded at Garvan to investigate new strategies for therapy

Professor Stuart Tangye and Dr Ira Deveson

Stuart-Tangye-Ira-Deveson-Garvan-Institute

Professor Stuart Tangye and Dr Ira Deveson have been recognised for their outstanding contributions to immunology and clinical genomics.

Garvan researchers honoured with NSW Premier’s Prizes

Professor-Stuart-Tangye-3_Garvan-Institute.jpg

Professor Stuart Tangye’s work advancing rare immune disease research has received national recognition.

Garvan immunologist awarded 2024 Eureka Prize

Professor Daniel MacArthur speaking at SXSW Sydney

SXSW_Daniel_MacArthur_Garvan-Institute.jpg

Researchers aim to collect genetic data from 10,000 diverse Australians to improve disease prediction, diagnosis and treatment for people from under-represented backgrounds.

Diverse Australians invited to shape future of genomic medicine

Dr David Herrmann and Professor Paul Timpson

Paul-Timpson-and-David-Hermann_Garvan-Institute.jpg

A new trial will test whether ‘priming’ pancreatic cancer can make it more susceptible to chemotherapy.

Pancreatic cancer clinical trial to test new approach to treatment

Peter_Croucher_Garvan_Institute

Professor Peter Croucher has been honoured with an award from the American Society for Bone and Mineral Research.

Prestigious bone research award for Professor Peter Croucher

190618_Alex-Swarbrick_Garvan-Institute

Research into predictive biomarkers at Garvan has been recognised internationally with a significant funding boost.

International fellowship for Garvan breast cancer researcher

Liz-Caldon-Garvan-Institute

By analysing more than 80 clinical trials, researchers at Garvan have identified genetic tests that predict which cancer patients are likely to benefit from PARP inhibitors in combination with chemotherapy.

Explore our research

Our impact

Our people

News and resources

About us

Support Us

News

Featured Article

Cellular ‘atlas’ of prostate cancer opens new avenues for earlier detection